Navigation Links
Better treatment selection and improved therapies -- key to improving prognosis in acute HF
Date:5/30/2009

Today, acute heart failure represents the most common reason for hospitalisation in the over-65 population. Although hospital care improves symptoms in the first 24 hours after admission in around 50% of these patients, acute heart failure events still remain associated with a more than 50% mortality and rehospitalisation rate at 6-12 months. "Indeed," says Professor Marco Metra from the Cardiology Department of the University of Brescia, Italy, "it is the very rapid onset of symptoms and the need for urgent therapy which characterise the condition."1,2

Treatments in acute heart failure, he adds, have not undergone any great change in recent decades, despite the demand of heart failure's increasing prevalence and huge personal and public impact. Professor Metra said that treatments are still based on loop diuretics (furosemide), peripheral vasodilators (nitrates) and inotropic agents. Even the more recently approved treatments, he added, such as levosimendan in Europe and nesiritide in the USA, have been associated with uncertain effects on outcomes in randomised trials. "So hospitalisations for acute heart failure are still associated with high mortality and rehospitalisation rates," he says. "The burden is tremendous because of the large number of patients involved, their poor prognosis and the costs of the treatment."

In a presentation at Heart Failure Congress 2009 Professor Metra defined two major pathways along which this burden might be reduced and treatment improved:

* Better selection of treatments. To date, he said, therapy in acute heart failure has been administered with little attention to the clinical presentation of each patient. Guidelines on heart failure issued by the European Society of Cardiology in 2008 define heart failure as a heterogeneous condition and recommend that different therapies are used on the basis of clinical presentation; for example, patients with fluid overload should undergo fluid removal through diuretics or other means, patients with high blood pressure should receive mainly vasodilators, and patients with low cardiac output should be treated with inotropic agents to improve the force of the heart muscle's contraction.3

* Improved therapies. Many new agents are currently under development, said Professor Metra, which include adenosine type 1 receptors antagonists to enhance the diuretic effects of furosemide and increase renal blood flow, new vasodilators with different mechanisms of action, and new inotropic agents.

"Better treatment selection and the development of new agents give us some hope that we will finally be able to improve the symptoms and prognosis of such a large patient population as that suffering from acute heart failure," says Professor Metra. However, he also emphasised that urgent therapy is one of the key recommendations of the latest European guidelines.


'/>"/>

Contact: ESC Press Office
press@escardio.org
33-062-241-8492
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
3. Informational handout key to giving parents a better understanding of CT radiation risks
4. Children of depressed moms do better when dad is involved, SLU researcher finds
5. Struggling male readers respond better to female teachers
6. Physician Skin Care Specialist Says Proposed New Rules for Sunscreen Products Will Better Protect the Public
7. Mothers Know Best: NFL Moms Team With Eddie George to Showcase a Better Way to a Healthier Lifestyle
8. Researchers Find Better Way to Deliver Blood Thinner
9. Clinical trials present better alternatives for dialysis patients
10. New nurses report job stress, need for better management
11. Hispanics hypertension better controlled with equal access to care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... 22, 2017 , ... Patients who avoid necessary dental and endodontic treatments because ... Kisco, NY from Advanced Endodontics of Westchester. This highly-trained team of endodontists offer three ... more sedation methods may be recommended based on the severity of the anxiety experienced ...
(Date:5/22/2017)... , ... May 22, 2017 , ... An inventor from ... with a pen. "My wife’s hand was damaged in a firework accident, so she ... helps people with manual problems." , He then designed and created a prototype for ...
(Date:5/22/2017)... ... May 22, 2017 , ... Faithfully following pop culture, people today are ... toned and shaped through fitness programs. It carries on to skin nourished, pampered and ... an irresistible, radiant smile. CDA has found that just like a perfectly ...
(Date:5/21/2017)... ... , ... Chris Cornell, 52, was found dead on the night of Wednesday, May 17, 2017. ... singers in the rock industry would take his own life, but the extremely talented and ... illness played a role in the death of Chris Cornell . , Depression and ...
(Date:5/21/2017)... Viejo, CA (PRWEB) , ... May 20, 2017 ... ... self-animating, paragraph styled corporate text designs created specifically for use in Final Cut ... editing process for all media productions. Pixel Film Studios’ ProParagraph Corporate will deliver ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
(Date:5/18/2017)... May 17, 2017  Bayer announced today that the ... be presented at the 53 rd Annual Meeting ... place June 2-6 in Chicago . ... span prostate, colorectal, liver and thyroid cancers, as well ... Phase II CHRONOS-1 trial of copanlisib in patients with ...
(Date:5/15/2017)... PHILADELPHIA , May 15, 2017 Enterin Inc., ... and developing novel compounds to treat Parkinson,s disease ... The study is a Phase 1/2a randomized, controlled, multicenter study ... sites. It will enroll 50 patients over a 9-to-12-month period. ... doses in 10 patients with PD. Participating sites include ...
Breaking Medicine Technology: